An observational study in Early Susceptibility-Weighted Imaging and Vessel-Wall Imaging Findings After Flow-Diversion Treatment of Intracranial Aneurysms, sponsored by Uludag University. Recruiting at 1 site in Turkey. Per ClinicalTrials.gov, last updated 2023-02-08.
Sponsored by Uludag University · Observational
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Intracranial Aneurysm with a site in Turkey — 5 open to participants now, 5 under way, none of them phase 3. Intracranial Aneurysm · Turkey.
Among the 10 studies in Intracranial Aneurysm with a site in Turkey, this one is the only one that started in 2022, is one of 5 observational ones, and was the 5th registered.
419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.
Browse Intracranial Aneurysm studies →5 of the 10 studies in Intracranial Aneurysm with a site in Turkey are open now. Recruiting first, the newest first:
Konya City Hospital · Sites in Turkey
Ages 18–65
Dokuz Eylul University · Sites in Turkey
Ages 18–75
Fatih Sultan Mehmet Training and Research Hospital · Sites in Turkey
Ages 18+
Fatih Sultan Mehmet Training and Research Hospital · Sites in Turkey
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 200 across 191 observational studies indexed under Intracranial Aneurysm.
Median enrollment 108 across the 5 interventional studies, 75 across the 5 observational. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 10 have an industry lead sponsor. The 9 most frequent:
Uludag University is the lead sponsor of 149 studies on the registry; 41 are open to participants now.
Uludag University has 1 study filed under Intracranial Aneurysm — fewer than ten, so there is no comparison to draw.
3 of the studies in Intracranial Aneurysm with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07859982Fatih Sultan Mehmet Training and Research HospitalHyperoxemia and Oxygen Reserve Index During Neurointerventional Anesthesia | 2027-04 |
| NCT07660861Fatih Sultan Mehmet Training and Research HospitalRemifentanil vs Esmolol During Intubation for Cerebral Aneurysm Coil Embolization | 2027-06-01 |
| NCT07910864Konya City HospitalEffect of Bilateral Greater Occipital Nerve Block on Headache After Intracranial Aneurysm Coiling | 2027-11-02 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Intracranial Aneurysm with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Purpose: Examination of microangiopathic changes that may develop after flow-directed stenting of intracranial aneurysms with susceptibility-weighted imaging (SWI), and vessel wall imaging (VWI) of vessel wall inflammation that may be associated with stenosis in the stented vessel and rupture of the aneurysm.
Methods: SWI and VWI examinations will be performed before and after treatment in patients who are planned for flow-directing aneurysm treatment. Clinical follow-up of the cases will be performed during the first 3 months post-procedure. At the end of the 3rd month, SAG and DDG findings related to and unrelated to intracranial hemorrhage will be detected by control imaging.
Susceptibility-weighted imaging (SWI) and vessel wall imaging (VWI) are among the most recent magnetic resonance (MR) techniques used to evaluate the cerebral vascular system (1,2). SWI; In addition to detecting the damage caused by many cerebrovascular pathologies at the microvascular level more sensitively than other imaging methods, it is the only MR sequence that can be used to differentiate blood-iron-calcification. It is the most sensitive MR sequence for iron accumulation and calcification. In addition to cerebrovascular diseases, it can be used in neurodegenerative diseases, especially parkinsonism, in the evaluation of tumoral - infective processes that can go with calcification (3). Similarly, VWI; It is used with increasing frequency in current practice in the diagnosis of pathologies affecting the vessel wall such as dissection, atherosclerotic change, inflammation and vasculitic involvement that cannot be clearly distinguished by normal vessel imaging methods (4). For both SWI and VWI, an MR device infrastructure with at least 3T magnetic field strength is required (2,5). Both techniques have limited diagnostic capabilities at magnetic field strengths up to 1.5T.
In studies conducted with VWI, it is stated that staining detected with VWI on the aneurysm wall may have predictive properties in terms of rupture (6,7). In addition, microhemorrhages detected by SWI imaging have been reported to transform into large parenchymal hemorrhages due to perfusion changes (8). Distant bleeding occurs due to perfusion change in some of the aneurysm cases that receive flow-directing therapy (9). In addition, rupture of the aneurysm may occur in some of the cases in which this treatment is applied, and stent stenocclusion may occur in some (10-11).
In the light of the above information, we aimed to evaluate the relationship between microhemorrhages, which may be a precursor of large parenchymal hemorrhages, staining of the aneurysm wall that may reflect the potential for rupture with VWI, and vessel wall staining or hematoma, which may reflect the risk of stenocclusion, with SWI examination to be performed on a 3T MR device in cases of intracranial aneurysms that were treated with flow-guided therapy, and complications developing after treatment.
References:
Study Protocol, Methods and Procedures:
Patients who are scheduled for endovascular treatment with a stent for their intracranial aneurysm following upgrading of the MR device will be included in the study. Cases will be divided into 3 groups according to the characteristics of aneurysms in digital subtraction angiography (DSA) examination. In Group 1, patients with a diameter greater than 8 mm and suitable for flow-guiding therapy, in Group 2. Patients with a diameter of less than 8 mm and suitable for flow-guiding therapy, in Group 3. Patients whose aneurysm is suitable for treatment with a metal-coated stent. will take. A total of 60 patients, 20 patients in each group, will be included in the study. Verbal and written informed consent will be obtained from all patients for imaging and treatments.
Patients to be included in the study will be examined in the last 24 hours prior to endovascular treatment in an elevated 3T MR device (preprocedural examination). SWI, VWI sequences will be obtained. In addition, the current neurological findings of the patients will be recorded. Control SWI and VWI sequences will be available within 48 hours of performing endovascular therapy (early postprocedural examination). In the preprocedural and postprocedural examinations, microbleeding foci detected in SWI and vessel wall inflammation findings observed in VWI will be recorded. Following the imaging, the clinic of the patients will be evaluated verbally on the 3rd day, 1st week, 1st month, 2nd month and 3rd month after treatment. In the 3rd month, the patient's neurological examination will be repeated and control SWI - VWI examinations will be performed (late postprocedural examination). Clinical symptoms that develop in the event of neurological deterioration will be recorded and the patient will be examined by cranial MR, cranial MR angiography and cranial computed tomography for intracranial bleeding, aneurysm rupture and stent occlusion. Cases out of follow-up will be excluded from the study.
In all 3 groups, the possible relationship between microhemorrhage foci in preprocedural, early and late postprocedural SWI and vessel wall inflammation findings in VWI and radiological findings such as bleeding or ischemia that may be related to worsening, worsening of clinical condition, various statistical findings, especially chi-square test. methods will be investigated. It will be evaluated whether the findings observed in SWI and VWI are predictive in terms of intracranial hemorrhage, aneurysm rupture and stent occlusion in patients who received current converter therapy. Findings that do not cause clinical symptoms and are observed in SWI and VWI will be determined in current converter cases. In addition, it will be investigated whether there is a significant difference between the SWI and VWI findings observed in the cases treated with current-converting treatment and those treated with metal-covered stent, and the possible effect of aneurysm size on SWI and VWI findings in cases treated with current-converting treatment.
Patients who are scheduled for endovascular treatment with a stent for their intracranial aneurysm following upgrading of the MR device will be included in the study. Cases will be divided into 3 groups according to the characteristics of aneurysms in digital subtraction angiography (DSA) examination. In Group 1, patients with a diameter greater than 8 mm and suitable for flow-guiding therapy, in Group 2. Patients with a diameter of less than 8 mm and suitable for flow-guiding therapy, in Group 3. Patients whose aneurysm is suitable for treatment with a metal-coated stent. will take. A total of 60 patients, 20 patients in each group, will be included in the study. Verbal and written informed consent will be obtained from all patients for imaging and treatments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Endovascular treatment plan with stent for intracranial aneurysm No kidney dysfunction history No MRI contrast material allergy history
Exclusion Criteria:
Pregnancy History of MR contrast material allergy Kidney dysfunction Leave Following-up During Study
Aneuryms treated with Flow-Diverting Stents and had a diameter above 8 mm
Diagnostic Test: Pre-procedural, early and late post-procedural susceptibility weighted imaging and vessel wall imaging with a 3T Magnetic Resonance Imaging Device · Procedure: Aneurysm Treatment with Flow-Diversion Therapy
Aneuryms treated with Flow-Diverting Stents and had a diameter below 8 mm
Diagnostic Test: Pre-procedural, early and late post-procedural susceptibility weighted imaging and vessel wall imaging with a 3T Magnetic Resonance Imaging Device · Procedure: Aneurysm Treatment with Flow-Diversion Therapy
Aneurysms treated with metalic bare stents
Diagnostic Test: Pre-procedural, early and late post-procedural susceptibility weighted imaging and vessel wall imaging with a 3T Magnetic Resonance Imaging Device · Procedure: Aneurysm Treatment with Metalic Bare Stent
Pre-procedural, early and late post-procedural susceptibility weighted imaging and vessel wall imaging with a 3T Magnetic Resonance Imaging Device
Aneurysm Treatment with Flow-Diversion Therapy
Aneurysm Treatment with Metalic Bare Stent
Determining Clinical Significant and Unsignificant Early Post-procedural susceptibility weighted and vessel wall imaging findings related to flow diversion treatment of intracranial aneurysms
Time frame: Post-procedural First Three Months
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2022 (actual). Primary completion is estimated for Dec 2024, 32 months after the start.
Of 68 non-industry observational studies under Intracranial Aneurysm, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 145. This study's planned 32 months is below that.
Counting every sponsor, half of 105 studies reached it within 46 months; a quarter within 36 and three quarters within 145.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.